CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 184 enrolled
Drug / intervention
Healon +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00763360
NCT00763360Phase 4Completed
CompareCT.gov

To Compare the Ability of DiscoVisc® Ophthalmic Viscosurgical Device (OVD) to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

Alcon Research·interventional·Posted Sep 30, 2008·Updated Jan 24, 2012

In Brief

A Phase 4 clinical trial evaluating DisCoVisc®, Healon, and 1 other intervention for Cataract. Completed, enrolled 184 participants across 1 site.

Detailed Summary

The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 30, 2008
Enrollment StartMay 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.8 years ago

Interventions

DisCoVisc®device

Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure

Healondrug

Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure

Amvisc Plusdrug

Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure